AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Gaining Momentum: Ex – President, Merck KGaA (Latin America), Lawrence Ganti joins Innoplexus as CEO, Americas
Innoplexus AG, a leading AI based analytics as a service provider in life sciences and financial services domain, announced today appointment of Lawrence Ganti as Chief Executive Officer of Innoplexus, Americas, further strengthening its leadership team.
Lawrence is widely respected as exceptional team builder and accomplished leader in Pharma Industry. His addition to leadership team will play crucial role in our company’s transformational journey”, said Dr. Gunjan Bhardwaj, Global CEO, Innoplexus.
Lawrence brings over 20 years of experience in healthcare, technology, and consumer goods where he has worked across general management, commercial development, strategy formulation, and marketing. Amongst his many achievements, Lawrence led the post merger integration of Merck and Serono’s international business; implemented a turnaround of Merck’s business in India; spearheaded a transformation of the Latin America operations; and launched an award winning marketing campaign in Japan.
Prior to joining Innoplexus, he built an impressive career over 14 years with Merck KGaA, where he held various leadership positions across Europe, Asia, and Latin America. Most recently Lawrence held the position of President – Latin America at Merck. He started his career with PepsiCo, Marriott, and Johnson & Johnson, then moved to McKinsey & Company before taking on business development roles for various technology startups. Lawrence holds an MBA from IMD In Switzerland and BS in Entrepreneurship from Babson College, USA. He will be based out of New Jersey, USA.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
